Full-Time
Posted on 5/30/2026
Global pharmaceutical company delivering science-based innovations
$236.6k - $439.4k/yr
Livingston, NJ, USA
In Person
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Help us improve and share your feedback! Did you find this helpful?
People at Novartis who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
On Clinical Trials Day, Howard University emphasizes trust and participation in research. May 20, 2026 2 minutes May 20 is Clinical Trials Day, and Howard University is marking the observance through ongoing efforts to improve trust and participation in clinical studies for communities traditionally overlooked in the research process. According to Celia J. Maxwell, professor of medicine and director of Howard University's Clinical Trials Unit, the university is currently involved in approximately 13 clinical trials, including studies in startup and contracting phases. Howard University's clinical trials program has also been strengthened through collaborations with industry partners such as Novartis and Sanofi, which help expand access to research and emerging treatments. "Clinical trials are highly regulated and include strict protections around participant privacy and study integrity," Maxwell says. "They are essential because they help determine whether treatments are safe and effective across diverse populations." At Howard University, ongoing clinical trial studies span a wide range of conditions, including asthma, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, eczema, hidradenitis suppurativa, chronic hives, heart disease, and chronic kidney disease. Maxwell said the goal is to expand access to emerging treatments while ensuring that communities most affected are represented in medical research. Historically, African Americans and other groups have been excluded from medical research, contributing to lingering mistrust shaped in part by the infamous Tuskegee Study. Maxwell said modern clinical trials now operate under strict safeguards, including informed consent, federal oversight, and ongoing safety monitoring. In recent years, Howard University and Howard University Hospital have also worked to strengthen their clinical research infrastructure. Investments have included expanded staffing, pharmacy capabilities, data systems, and community outreach efforts designed to support long-term growth in clinical research. Maxwell noted several ways for Howard students and community members to become involved in clinical research. Individuals can learn about ongoing studies and opportunities through resources such as ClinicalTrials.gov, Howard University's Office of Regulatory Research Compliance, university outreach events, community health programs and fairs, training and mentorship opportunities, and CITI research training programs. She added that students interested in research careers can seek opportunities through faculty mentorship, clinical research training programs, internships, and volunteer experiences connected to ongoing studies. Observed globally each May 20, Clinical Trials Day recognizes the anniversary of what is considered the first randomized clinical trial, conducted in 1747 by British naval surgeon James Lind to study treatments for scurvy among sailors. Today, the observance also provides an opportunity to educate the public about the importance of clinical trials in advancing medicine and improving patient care. Jul 28, 2021 4 minutes Jun 22, 2022 4 minutes Are you a member of the media? Its public relations team can connect you with faculty experts and answer questions about Howard University news and events.
How can Impactstewards improve heart failure care? Heart failure is a serious condition with a significant impact on the daily lives of patients and their loved ones. Fortunately, over the past decade, there have been many advancements in heart failure care. However, understandably, these improvements have not yet been fully implemented everywhere in the Netherlands. This prompted Impact Stewards and Novartis to join forces. Impactstewards gathered insights from cardiologists at six hospitals and compiled them into the Practice Paper: Heart Failure Care of the Future. Why improving heart failure care doesn't happen automatically. Developments in heart failure care have advanced rapidly over the past ten years. New scientific insights, guidelines, home monitoring tools, and communication channels have emerged. Yet, implementing these improvements in heart failure care does not always take off smoothly. As a result, a patient may have a higher chance of receiving guideline-based treatment in one hospital compared to another. In the daily hustle of clinical care, it can be challenging for heart failure teams to address this systematically. Six hospitals share how they improve heart failure care. As a pharmaceutical company, Novartis is in contact with almost all cardiologists in the Netherlands. It asked Impact Stewards for help: Could Impactstewards collaborate to gather insights from centres with outstanding examples of innovative heart failure care? This way, cardiologists can learn from each other more quickly. In the Practice Paper: Heart Failure Care of the Future, Impactstewards compile insights from six hospitals. Cardiologists from Catharina Hospital, Maastricht UMC+, Pantein Maasziekenhuis, Rijnstate, Spaarne Gasthuis, and St. Antonius share their experiences. How have they implemented new guidelines and improved the accessibility and quality of cardiological care? And how are they preparing for the heart failure team of tomorrow? What does the future of heart failure care look like? Six hospitals share how they have structured their heart failure care. What does the future of heart failure care look like? The paper includes recommendations to improve heart failure care: * Rapidly achieving Optimal Medical Therapy (OMT) in an outpatient setting * Home monitoring and restructuring patient support * Developing a standardised and multidisciplinary care pathway * Facilitating and encouraging self-management * Gaining insights through data analysis of the patient population * Optimal collaboration within the heart failure team The Practice Paper: Heart Failure Care of the Future is now available to healthcare providers via Novartis: "We created a Practice Paper with examples from six centres, showing how they improve heart failure care. By learning from others, you can implement these improvements faster." - Naomi Tielen, Impact Steward How Impact Stewards contributes. Impact Stewards helps organisations in healthcare and life sciences do better - for patients and the planet. Its mission is to improve the accessibility, affordability, and sustainability of its healthcare system. Its Impact Stewards are seasoned experts in healthcare and life sciences. Together, Impactstewards oversee the entire healthcare system: from medical innovation to patient care. Impactstewards leverage its sector knowledge, advisory skills, and transformation expertise to achieve sustainable change. In this project, Impact Stewards serves as an independent partner. Impactstewards represent the interests of all stakeholders and ensure the neutrality, transparency, and diligence of the process, decision-making, and outcomes as described in this Practice Paper.
Novartis Romania hires Alexandra Banas as Head of Legal. * Saida Ayupova * May 8, 2026 Alexandra Banas has joined Novartis Romania as its Head of Legal. Prior to joining the pharmaceutical company, Banas was the Head of Legal & Compliance SEE at Reckitt between 2020 and 2025. Before moving in-house, she worked as a Lawyer at GPA Law between 2018 and 2020, at Vernon | David between 2016 and 2018, at Fatu & Asociatii between 2014 and 2016, and at JGV si Asociatii between 2008 and 2012. "Alexandra joins us as Legal Head and brings with her a solid experience in legal strategy, compliance, and business partnership," a company statement read. "She strongly believes in collaboration and in supporting teams to perform, and we are glad to have her by our side!" Get the memo - every week. Essential in-house updates, straight to your inbox. * Saida Ayupova * May 14, 2026 Pobric joined the bank in 2024 as the Head of the Legal Affairs Department. Prior to ZiraatBank BH, she spent nine years at BBI Bosna Bank International. * Radu Cotarcea * May 11, 2026 Karanikola joins the telecommunications company from Ademu, where she was a Chief Operating and Legal Officer between 2024 and 2026. * Radu Cotarcea * May 6, 2026 Danielova joined the real estate company in 2023 as an Attorney. Earlier, she worked as a Lawyer at UniCredit Bank Czech Republic and Slovakia between 2019 and 2022.
Novartis closes factory in Wehr: 220 jobs cut. Pharma giant in Wehr Novartis closes factory near Swiss border - 220 jobs affected. The Swiss pharma giant is closing its production site in the southern German town of Wehr. It is no longer competitive. Published: 05.05.2026, 12:05 Swiss pharmaceutical giant Novartis plans to close its production site in Wehr, Baden-Württemberg, by the end of 2028. The Basel-based company announced that around 220 jobs would be cut. The reason for the decision: the site in the Waldshut district is no longer competitive. "We are aware of the uncertainty this announcement brings for our colleagues at the Wehr site," said production chief Steffen Lang. The company wants to work transparently and respectfully with employees and the municipality of Wehr. The Wehr site currently produces tablets and capsules. Novartis stressed that patient supply would not be endangered by the closure. The company reaffirmed its commitment to Germany as a location. At the same time, Novartis is investing 35 million euros in a new production facility for cancer therapies in Halle, Saxony-Anhalt, which is scheduled to start operations in 2027. According to its own information, Novartis employs over 2,600 people at six sites in Germany. Economy today Get the most important news from the economy, along with the best background information and analyses. More newsletters
NEW: Trump celebrates tariff triumph at steel rally, sparks manufacturing boom. At a lively gathering at the Coosa Steel plant in Rome, Georgia, former President Donald Trump proclaimed the triumph of his administration's tariffs as a catalyst for revitalizing American manufacturing. This rally, held on February 19, was infused with a sense of victory among supporters who attribute their economic recovery to Trump's policies. The focus on tariffs underscored their significance in this perceived resurgence. Andrew Saville, the president of Coosa Steel, gave a passionate endorsement of the tariffs, stating, "All the jobs that were going to China, you brought them back, and it really took us to the next level!" His words illuminated the transformation at Coosa Steel, going from the brink of failure to operating at full capacity. Saville emphasized the toll that foreign competition had taken on domestic businesses, noting, "The thing that took us right to the top was your tariffs. I think everybody in here that runs a small business, the tariffs had an effect on you one way or another." This endorsement served as powerful evidence of the impact Trump's trade policies have had on local industries. The rally served not only as a platform for Trump's economic discourse but also as a means of supporting a roster of Republican candidates leading up to upcoming elections. Coosa Steel Corporation became a symbol of the agenda aimed at restoring American jobs by protecting local manufacturing from international competition. Initially introduced during Trump's presidency, the tariffs included heavy taxes on foreign steel to counteract the low-price competition from countries like China. Trump framed these tariffs as essential to his strategy for rejuvenating American manufacturing, imposing fees of up to 50% on imported steel and its derivatives to champion domestic production. Steel workers at Coosa reaffirmed their support for these policies. Employee Jeffrey Shook remarked, "Our trucks are rolling out of here at near-max capacity every day," echoing Tyler King's observation that, "Business is climbing every day." These statements reflect a significant increase in productivity and activity since the implementation of tariffs, aligning with claims of economic revitalization. While some economists have questioned the effectiveness of protectionist tariffs, the rally functioned as a robust counter-argument. Trump, backed by White House officials, shared estimates claiming tax savings exceeding $3,000 per family in Georgia, along with promises of wage increases of approximately $6,700 for workers over the next few years. This gathering wasn't limited to the steel industry; it showcased a broader trend of business investments throughout Georgia. Major companies like Amazon and Salesforce were highlighted as key players in driving infrastructure development and job growth, emphasizing an ongoing theme of American economic renewal. However, not all was uncontested. Trump made strong claims regarding lower drug prices and job safeguarding that lacked extensive independent verification. Nonetheless, the rally retained a patriotic and revivalist theme, presenting policy-driven narratives designed to garner support within Georgia's political climate. The event underscored an underlying current of economic nationalism that Trump has championed. The development of Novartis' plan to construct drug manufacturing plants in the U.S., incentivized by tariffs, was pointed out as another indication of this economic turnaround. Saville referred to the improvement in business conditions as a "game changer," with orders and production possibilities reaching new levels. As the rally concluded, Trump reiterated his administration's achievements as a roadmap for America's future, placing them in stark contrast to the economic strategies of the current administration. By blending economic policy with electoral campaigning, the rally aimed to celebrate tangible successes while rallying support as the political landscape in Georgia shifts. Overall, the event at Coosa Steel represented a significant chapter in an era focused on prioritizing domestic interests over international ones. Supported by endorsements like Saville's, Trump's tariffs and their purported successes have emerged as a foundational element of his political and economic narrative.